Literature DB >> 1371719

Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fraction.

E Kuramoto1, O Yano, S Shimada.   

Abstract

MY-1, which consists of DNA and RNA extracted and purified from bacillus Calmette-Guérin (BCG), has been shown to have strong antitumor activity against various experimental tumors. To examine the role of T cells in the antitumor mechanism of MY-1, the effect of MY-1 injection on the development of tumor-specific immunity against MethA fibrosarcoma was investigated. MY-1 injections inhibited tumor growth less effectively in T-cell-deficient nude mice than in normal BALB/c mice. MethA tumor growth was suppressed after inoculation with L3T4-positive lymphocytes from tumor-bearing mice treated with MY-1. MethA-specific delayed-type hypersensitivity was also detected in tumor-bearing mice treated with MY-1. Immunohistochemical analyses showed that many L3T4-positive and a few Lyt2-positive cells infiltrated the regressing tumors. These results indicate that intratumoral MY-1 injections induce a MethA-specific, L3T4-positive cell-mediated, delayed-type hypersensitivity, which is necessary for the tumor regression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371719     DOI: 10.1007/bf01741547

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

1.  Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.

Authors:  H J WINN
Journal:  J Immunol       Date:  1961-02       Impact factor: 5.422

2.  Expression of asialo GM1 on a subset of adult murine thymocytes: histological localization and demonstration that the asialo GM1-positive subset contains both the functionally mature and the proliferating thymocyte subpopulations.

Authors:  J Suttles; G A Schwarting; M W Hougland; R D Stout
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

3.  Interferon-activated tumor inhibition in vivo. Small amounts of interferon-gamma inhibit tumor growth by eliciting host systemic immunoreactivity.

Authors:  M Giovarelli; F Cofano; A Vecchi; M Forni; S Landolfo; G Forni
Journal:  Int J Cancer       Date:  1986-01-15       Impact factor: 7.396

4.  In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG.

Authors:  S Shimada; O Yano; T Tokunaga
Journal:  Jpn J Cancer Res       Date:  1986-08

5.  Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.

Authors:  M Prat; S Bretti; M Amedeo; S Landolfo; P M Comoglio
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

6.  The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice.

Authors:  H Ozawa; T Iwaguchi; T Kataoka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Tumor dependency of concanavalin A-induced potentiation of tumor cell immunogenicity.

Authors:  T Kataoka; F Oh-hashi; Y Akabori; Y Sakurai; M Okabe; K Gomi
Journal:  Gan       Date:  1983-06

8.  Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations.

Authors:  M Rosenstein; T J Eberlein; S A Rosenberg
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

9.  A glycolipid on the surface of mouse natural killer cells.

Authors:  M Kasai; M Iwamori; Y Nagai; K Okumura; T Tada
Journal:  Eur J Immunol       Date:  1980-03       Impact factor: 5.532

10.  Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.

Authors:  T Tokunaga; H Yamamoto; S Shimada; H Abe; T Fukuda; Y Fujisawa; Y Furutani; O Yano; T Kataoka; T Sudo
Journal:  J Natl Cancer Inst       Date:  1984-04       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.